Safety and Efficacy of T Cell Genetic Immunotherapy for HIV

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00131560
Recruitment Status : Active, not recruiting
First Posted : August 18, 2005
Last Update Posted : June 8, 2011
Information provided by:
VIRxSYS Corporation

August 16, 2005
August 18, 2005
June 8, 2011
July 2005
November 2008   (Final data collection date for primary outcome measure)
  • Change in viral load [ Time Frame: 1 Year ]
  • Change in CD4 counts [ Time Frame: 1 Year ]
  • Safety [ Time Frame: 15 Years ]
Change in viral load, change in CD4 counts, safety
Complete list of historical versions of study NCT00131560 on Archive Site
  • Immune function [ Time Frame: 1 Year ]
  • AIDS related illness [ Time Frame: 1 Year ]
  • Persistence of vector modified cells [ Time Frame: 15 Years ]
Immune function, AIDS related illness, and persistence of vector modified cells.
Not Provided
Not Provided
Safety and Efficacy of T Cell Genetic Immunotherapy for HIV
A Phase II, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, and Biological Activity of Single and Repeated Doses of Autologous T Cells Transduced With VRX496 in HIV-Positive Subjects
This study uses autologous (one's own) CD4 T cells modified with a viral vector expressing a genetic antisense targeting HIV, this vector is called VRX496. Study treatment is by intravenous infusion of vector modified cells and infusions will be provided every other week for a total of 4 or 8 doses. These modified cells, once infused, may provide immune support and are not destroyed by HIV, and thus may delay or reverse HIV disease progression. The study will enroll up to 40 male and female HIV-positive subjects in up to 8 centers. Subjects will be 18 years of age and over who have failed or are intolerant to at least one triple combination of antiretroviral drugs. Subjects must have a viral load between 5,000 and 200,000 copies/ml and a CD4+ count of ≥150, be in good health and have no evidence of active opportunistic infection, heart disease, or bleeding disorders. Subjects must not be on corticosteroids, immunomodulating agents or hydroxyurea. Subjects must not have received an AIDS vaccine or any investigational gene therapy product at any time. Females must not be pregnant or breastfeeding.

VIRxSYS has concluded a 6-month Phase 1/2 clinical study under an IND of the vector VRX496 in HIV-positive subjects who have failed at least two HAART regimens. HAART typically consists of a triple "cocktail" of drugs. Although these cocktails have been successful in reducing viral loads and restoring immune function, they do not represent a cure. There are also concerns about adverse effects associated with long-term usage of HAART. Specifically, a variety of metabolic disorders including HIV-associated lipodystrophy, central adiposity, dyslipidaemia, hyperlipidaemia, hyperglycemia, and insulin resistance have been reported as resulting from HAART. These reactions, combined with often complex and cumbersome dosing regimens, can have an adverse effect on patient-subject adherence to therapy. Furthermore, poor adherence has led to increased rates of HIV resistance, resulting in viral strains that have reduced sensitivity to the drugs. Importantly, in the Phase 1/2 clinical trial conducted by VIRxSYS, there were no reported toxicities associated with the product.

Gene therapy for HIV-1 infection has been proposed as an alternative to antiretroviral drug regimens. A number of different genetic vectors with antiviral payloads have been utilized to combat HIV-1, including antisense RNA, transdominant proteins, ribozymes, RNA decoys, single chain antibodies, and RNAi (RNA-interference. Antisense RNA targeted to wt-HIV RNA offers a significant advantage over several other genetic antiviral approaches because it is not a protein and thus not immunogenic and because the size of the payload prevents virus escape mutants, such as occurs with the use of RNAi.

In this Phase 2 protocol, 6 subjects will be staggered for infusion by at least 2 weeks. The first group of 3 subjects will receive 4 infusions (4-dose cohort). If no dose limiting toxicities (DLT) are observed, the second group of 3 subjects, (i.e. subjects 4, 5 and 6) will continue with 8 infusions (8-dose cohort). Safety visits are scheduled 1 week after infusion and monthly for the first 6 months and at 9 months following the last infusion.

After safety has been evaluated, and in order to explore biological activity, additional subjects (6-10 evaluable subjects) will be entered into each cohort. Follow-up visits are scheduled 1 week after infusion and monthly for the first 6 months and at 9 months following the last infusion.

The effect of a single bolus will also be examined in a third cohort. The single bolus infusion will consist of the following cell doses: approximately 10 billion, 20 billion, and 30 billion, respectively. Subjects will be allotted to the respective cell dose groups according to the order in which they are enrolled. Three to 5 subjects will be allotted to the lower cell dose group and followed for safety for 4 weeks. After safety is evaluated, the next group (3 to 5 subjects) will be allotted to the next higher cell dose group and followed for safety for 4 weeks. If the intermediate cell dose group is determined to be safe, an additional 3 to 5 subjects will be allotted to the highest cell dose group. All subjects will be followed for safety at biweekly intervals for the first 4 weeks and thereafter at monthly intervals up to 6 months and then at 9 months.

The study has concluded it's 9-month active phase. Subjects are currently in a 15-year Long Term Follow-up Phase of the study.

In keeping with the recently released Guidance on Monitoring For Delayed Adverse Events, that states that for the first 5 years all subjects should undergo monitoring of vector sequences every 6 months, subjects will visit the clinic at a maximum of 6 months intervals for a blood test evaluating persistence of vector sequences.

Therefore for the first 5 years, subjects will have 6 months visits for safety assessment. For years 6 to 15, subjects will be contacted by phone or mail. At these contacts, subjects will be asked about their health status.

Phase 2
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
HIV Infection
Genetic: VRX496-Modified Autologous T cells
Genetic: Anti-HIV antisense
Intervention: Genetic: VRX496-Modified Autologous T cells

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Active, not recruiting
June 2023
November 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Sero-positive for infection with HIV and failed, or be intolerant to, at least one triple combination of antiretroviral agent
  • If on antiretroviral therapy, subject must be willing to continue on current antiretroviral therapy; or if discontinues antiretroviral therapy must have a wash-out period of 6 weeks prior to screening; or if not on antiretroviral therapy must be willing to remain off antiretroviral therapy for the duration of the study (i.e. up to 1 year)
  • Male or female, 18 years of age and older
  • Karnofsky Performance score of 80 or higher
  • Stable HIV viral load between 5,000 and 200,000 copies/mL at the time of screening. Stable will be defined as a variation of less than 0.5 log10 in the 3 months prior to screening while on a stable regimen or no therapy
  • CD4 T cell count equal to or greater than 150 cells per μL at the time of screening
  • A body weight greater than 50 Kg
  • Adequate venous access and no other contraindications for leukapheresis
  • Subject must be willing to comply with study-mandated evaluations

Exclusion Criteria:

  • A history of any type of cancer or malignancy, with the exception of (successfully) treated basal cell or squamous cell carcinoma of the skin
  • A history or any features on physical examination indicative of cardiac disease or hemodynamic instability
  • Any history or any features on physical examination indicative of a bleeding diathesis
  • Previous treatment with any HIV experimental vaccine or any gene therapy products
  • A positive signal for VSV-G antibodies and/or VSV-G DNA in the blood at screening
  • Any of the following lab results:

    • Hemoglobin: <10 (males); <9.5 (females) g/dL
    • Absolute neutrophil count: < 1000/μL
    • Platelet count: <100,000/mm3
    • Serum creatinine: > 1.5 mg/dL (133µ mol/L)
    • AST or ALT: > 2.5 times the upper limit of normal
    • Total serum bilirubin: > 1.5 times the upper limit of normal
    • Proteinuria: 2+ on urine dipstick
  • Subjects must not be breastfeeding, be pregnant, or unwilling to use acceptable methods of birth control
  • Subjects must not be on chronic oral corticosteroids within 30 days of screening - (if subjects are prescribed a brief course of oral corticosteroids the use should be limited to less than 1 week), hydroxyurea, or immunomodulating agents (e.g., IL 2, interferon-gamma, granulocyte colony stimulating factors, etc.) within 30-days of screening or foreseeably need any of these within the study period
  • Subjects must not be using aspirin, dipyridamole, warfarin or any other medication likely to affect platelet function or other aspects of blood coagulation during the period when leukapheresis is scheduled
  • Subjects must not suffer from active drug or alcohol dependence or abuse, to an extent that, in the opinion of the investigator, would interfere with their ability to comply with study requirements
  • Any serious illnesses or acute opportunistic infection
  • Any other illness or condition which in the opinion of the investigator would exclude the subject from the study
  • Subjects unable or unwilling to give written informed consent
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Tessio Rebello/ Vice President Clinical Affairs, VIRxSYS Corporation
VIRxSYS Corporation
Not Provided
Study Director: Tessio Rebello, PhD VIRxSYS Corporation
VIRxSYS Corporation
June 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP